NeonMind Biosciences Inc

At NeonMind Biosciences, we believe in “mind over matter”. We plan to help people change their lives by changing their minds, through treatment with psychedelics.

Recent News

  • NeonMind Lists on the Frankfurt Stock Exchange

    Vancouver, British Columbia--(Newsfile Corp. - January 19, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) ("NeonMind"), a psychedelic drug development company, is pleased to announce its common shares are now trading on the Frankfurt Stock Exchange (the "FSE") under the symbol "6FU". As a result, NeonMind's common shares are now cross-listed on the Canadian Securities Exchange and the FSE.

    2021-01-19 2:00 AM ET
  • NeonMind Appoints Dr. Frank Russo to Lead Development of Music-Based Program for Psilocybin Clinical Trials

    Vancouver, British Columbia--(Newsfile Corp. - January 14, 2021) - NeonMind Biosciences Inc. (CSE: NEON) ("NeonMind") a company conducting research into the potentially therapeutic uses of compounds found in psychedelic mushrooms, is pleased to announce that it has added Frank Russo as an advisor and consultant to assist the Company in selecting or developing music playlists for its clinical trials or for use with treatments to support optimum mental health.

    2021-01-14 6:30 AM ET
  • NeonMind Engages Dr. C. Laird Birmingham to Develop Protocols for Phase 2 Clinical Trial Using Psilocybin to Treat Obesity

    Vancouver, British Columbia--(Newsfile Corp. - January 12, 2021) - NeonMind Biosciences Inc. (CSE: NEON) ("NeonMind"), a psychedelic drug development company, is pleased to announce that it has engaged Dr. C. Laird Birmingham to consult with NeonMind to develop protocols for its Phase 2 Clinical Trial administering psilocybin to treat obese patients. Dr. Birmingham is a Specialist in Internal Medicine, an Epidemiologist and Biostatistician, and a Professor of Psychiatry at the University of British Columbia where he was previously Professor of...

    2021-01-12 6:30 AM ET
  • NeonMind Announces Grants Pursuant to Stock Option Plan

    Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) -  NeonMind Biosciences Inc. (CSE: NEON) ("NeonMind"), a psychedelic drug development company, granted a total of 5,940,000 incentive stock options. 250,000 were granted to directors, 4,900,000 were granted to officers and 790,000 were granted to consultants under the Company's incentive stock option plan (the "Plan"). The options are exercisable into common shares of the Company at a price of $0.25 per share and are subject to a hold period of four months...

    2021-01-11 8:01 PM ET
  • NeonMind Appoints Trevor Millar as Chief Psychedelic Officer

    Vancouver, British Columbia--(Newsfile Corp. - January 7, 2021) - NeonMind Biosciences Inc. (CSE: NEON) ("NeonMind"), a company conducting research into the potentially therapeutic uses of compounds found in psychedelic mushrooms and commercializing medicinal mushroom products, is pleased to announce that it has appointed Trevor Millar as Chief Psychedelic Officer of NeonMind as of January 6, 2021.NeonMind Appoints Trevor Millar as Chief Psy

    2021-01-07 6:30 AM ET
  • NeonMind Commences Trading Under CSE Ticker Symbol "NEON"

    Vancouver, British Columbia--(Newsfile Corp. - January 4, 2021) - NeonMind Biosciences Inc. (CSE: NEON) ("NeonMind") is pleased to announce that its common shares have today commenced trading on the Canadian Securities Exchange (the "Exchange") under the ticker symbol "NEON". More information on NeonMind can be found at www.neonmindbiosciences.com.

    2021-01-04 6:00 AM ET
  • NeonMind Announces Closing of Oversubscribed Initial Public Offering and Exercise in Full of the Agent's Over-Allotment Option

    Vancouver, British Columbia--(Newsfile Corp. - December 30, 2020) -  NeonMind Biosciences Inc. (CSE: NEON) ("NeonMind"), is pleased to announce that it has successfully completed the maximum offering for its initial public offering (the "IPO") of 46,000,000 units of NeonMind (the "Units") at a price to the public of $0.10 per Unit, including 6,000,000 in additional Units pursuant to the exercise in full of the over-allotment option. The gross proceeds from the IPO, before deducting agent fees and estimated offering expenses,...

    2020-12-30 6:06 PM ET